Table 4. Hemostatic markers in the two study groups during the period.
Time ( n int / n ctr ) | Intervention | Controls | p- Value | |
---|---|---|---|---|
F 1+2 (pmol/L) | Baseline (22/21) | 210.80 ± 185.96 | 196.69 ± 60.30 | 0.11 |
6 mo (17/19) | 190.88 ± 55.41 | 235.86 ± 84.04 | ||
12 mo (22/21) | 203.14 ± 57.60 | 256.19 ± 222.25 | ||
D-dimer (ng/mL) | Baseline (22/21) | 349.38 ± 147.48 | 355.62 ± 140.54 | 0.26 |
6 mo (18/20) | 449.34 ± 263.07 | 458.10 ± 251.50 | ||
12 mo (22/21) | 479.24 ± 311.65 | 356.87 ± 126.94 | ||
Fibrinogen (g/L) | Baseline (22/21) | 3.38 ± 0.62 | 3.13 ± 0.52 | 0.70 |
6 mo (17/19) | 3.36 ± 0.69 | 3.36 ± 0.56 | ||
12 mo (21/21) | 3.43 ± 0.83 | 3.12 ± 0.54 | ||
FVIIAg (%) | Baseline (21/21) | 100.45 ± 16.75 | 100.99 ± 14.65 | 0.046 |
6 mo (16/20) | 108.65 ± 21.69 | 103.54 ± 17.23 | ||
12 mo (21/21) | 110.35 ± 20.21 | 104.82 ± 14.98 | ||
Total TFPI (ng/mL) | Baseline (21/21) | 63.47 ± 11.94 | 61.94 ± 14.49 | 0.28 |
6 mo (16/20) | 66.59 ± 15.07 | 63.16 ± 14.54 | ||
12 mo (21/20) | 65.40 ± 17.05 | 62.46 ± 14.08 | ||
Free TFPI (ng/mL) | Baseline (21/21) | 8.36 ± 2.75 | 7.93 ± 2.64 | 0.71 |
6 mo (16/18) | 10.31 ± 3.45 | 10.24 ± 3.09 | ||
12 mo (21/20) | 10.72 ± 4.65 | 9.94 ± 3.55 | ||
vWF (pg/mL) | Baseline (21/21) | 114.73 ± 21.80 | 105.45 ± 18.67 | 0.26 |
6 mo (16/19) | 129.24 ± 26.85 | 126.75 ± 23.79 | ||
12 mo (21/20) | 125.75 ± 26.68 | 118.08 ± 18.36 |
Note: Values are means ± standard deviation. The p -values are obtained from the fixed group effect from the ANCOVA mixed model with baseline values as covariates. FVIIAg is measured as % of normal plasma pool. “Time ( n int / n ctr )” represents the time of the sampling and the number of samples available for biomarker analysis from the intervention ( n int ) and control group ( n ctr ).
Abbreviations: F 1+2 , prothrombin fragment 1 + 2; FVIIAg, coagulation factor VII antigen; TFPI, tissue factor pathway inhibitor; VWF, von Willebrand factor.